Overview

Overview

Gmax Biopharm International Limited is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and M-Body development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. Founded in 2010, GMAX has attracted a talent pool of young scholars and US returnees. The core leadership for R&D has averaging 20 years of extensive biopharmaceutical industry experiences in multinational companies like Amgen, BMS and Genentech. Leveraging its proprietary world class GPCR antibody and M-Body platforms, GMAX has established a robust pipeline for diabetes, obesity, NASH, PAH and heart failure:  We have 6 clinical development programs, 2 IND filing program and more than 10 in preclinical studies.